Inventiva (IVA) Return on Capital Employed (2020 - 2021)

Inventiva (IVA) recorded quarterly Return on Capital Employed of 55.61% in Q2 2021, down 23.07% quarter-over-quarter from 45.19% in Q1 2021.

Inventiva (IVA) Return on Capital Employed (2020 - 2021) Analysis & Trends

Inventiva's Return on Capital Employed history runs 2 years deep, the most recent figure standing at 55.61% for Q2 2021.

In Q2 2021, Return on Capital Employed changed N/A year-over-year to 55.61%; the TTM figure through Jun 2021 stood at 55.61% (changed N/A YoY), while the FY2025 annual figure was 138.27%, down 51023.0% from the prior year.
Return on Capital Employed was 55.61% for Q2 2021 at Inventiva, down from 45.19% in the prior quarter.
In the past five years, Return on Capital Employed ranged from a high of 45.19% in Q1 2021 to a low of 82.87% in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROCE (Qtr)
1	Alterity Therapeutics	788,338.31 Bn	788,338.28 Bn	-	-
2	Belite Bio	56,560.00 Bn	56,560.00 Bn	-	-
3	Quantum Biopharma	17,329.30 Bn	17,329.30 Bn	-	450.31%
4	Legend Biotech	3,341.00 Bn	3,340.71 Bn	242.10 Mn	51.73%
5	Akari Therapeutics	1,727.91 Bn	1,727.91 Bn	-	-107.40%
6	Evaxion A	1,536.68 Bn	1,536.67 Bn	-	-
7	Psyence Biomedical	238.34 Bn	238.33 Bn	-	-
8	Vertex Pharmaceuticals	113.42 Bn	106.17 Bn	2.59 Bn	21.10%
9	Abivax	95.45 Bn	95.45 Bn	-	-50.43%
10	Inventiva	8.93 Mn	-259.80 Mn	-	-

Download Data